Biotech Inventions May Be More Easily Deemed Obvious Under Court Ruling
Executive Summary
An appeals court ruling that limits the patenting of DNA sequences could have negative repercussions for the industry
You may also be interested in...
Big Stakes In Lilly Patent Battle: How Broadly Can Patent Claims Be Written?
As Lilly and Ariad get back in the ring for another round in a major patent battle, those on the sidelines are closely watching the match as it could determine how broadly patent claims may be written. At issue is the question of what constitutes an adequate description of an invention
Big Stakes In Lilly Patent Battle: How Broadly Can Patent Claims Be Written?
As Lilly and Ariad get back in the ring for another round in a major patent battle, those on the sidelines are closely watching the match as it could determine how broadly patent claims may be written. At issue is the question of what constitutes an adequate description of an invention
ANDA Challenges To Formulation Patents May Get Easier After KSR Ruling
The pharmaceutical industry could have a tougher time protecting certain drug patents - particularly those in ANDA litigation - following a U.S. Supreme Court decision that expands the situations under which an invention can be considered obvious
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: